Advanced Solid-Liquid Fragment Synthesis of Leuprorelin for Commercial API Manufacturing

Advanced Solid-Liquid Fragment Synthesis of Leuprorelin for Commercial API Manufacturing

The pharmaceutical industry continuously seeks robust, scalable, and cost-effective methodologies for producing complex peptide therapeutics like Leuprorelin (CAS 53714-56-0). A significant technological advancement in this domain is detailed in patent CN112279893A, which discloses a novel method for synthesizing Leuprorelin via polypeptide solid-liquid fragments. This approach strategically combines the precision of solid-phase peptide synthesis (SPPS) for the N-terminal fragment with the efficiency of liquid-phase coupling for the C-terminal segment. By utilizing 2-chlorotrityl chloride (CTC) resin as the solid support and employing piperazine as the N-alpha-Fmoc deprotecting agent, this process addresses critical bottlenecks associated with traditional synthesis routes. The innovation lies not merely in the sequence of reactions but in the holistic optimization of reagent selection and resin management, offering a pathway to high-purity intermediates suitable for rigorous commercial API manufacturing standards.

The Limitations of Conventional Methods vs. The Novel Approach

The Limitations of Conventional Methods

Historically, the industrial production of Leuprorelin has relied heavily on standard Fmoc-solid phase strategies using resins such as HMPB-AM or chlorinated resins functionalized with mercaptoethylamine. These conventional pathways often suffer from significant logistical and economic drawbacks. For instance, traditional methods frequently utilize piperidine as the standard uncapping reagent for removing the Fmoc protecting group. Piperidine is not only relatively expensive but also presents challenges regarding toxicity classification, storage stability, and regulatory compliance due to its potential for deterioration and hazardous nature. Furthermore, the resins used in older protocols often lack efficient recycling mechanisms, leading to substantial solid waste generation and increased raw material costs per kilogram of final product. The reliance on single-mode synthesis (either purely solid or purely liquid) often results in cumulative yield losses or difficulties in purifying intermediate fragments, complicating the supply chain for high-volume production.

The Novel Approach

The methodology outlined in patent CN112279893A introduces a hybrid solid-liquid fragment condensation strategy that effectively circumvents these legacy issues. By synthesizing the N-terminal heptapeptide fragment (Compound 1) on CTC resin and the C-terminal dipeptide fragment (Compound 2) in the liquid phase, the process maximizes the strengths of both techniques. The use of CTC resin allows for mild acid cleavage conditions that preserve sensitive side-chain protecting groups until the final global deprotection step. Moreover, the substitution of piperidine with a dilute piperazine solution (2-5% mass concentration in DMF) for Fmoc removal represents a pivotal cost-saving measure. This novel approach ensures that the synthesized fragments can be conveniently produced, potentially automated, and that the solid support itself can be regenerated and reused, thereby drastically simplifying the overall process flow and enhancing the economic viability of large-scale Leuprorelin manufacturing.

Mechanistic Insights into Polypeptide Solid-Liquid Fragment Condensation

The core of this synthesis relies on the precise assembly of amino acid monomers using orthogonal protecting group strategies. In the solid-phase portion, the synthesis proceeds from the C-terminus to the N-terminus on the CTC resin. The process initiates with the loading of Fmoc-Leu-OH onto the resin, followed by sequential couplings of Fmoc-D-Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-His(Boc)-OH, and finally Boc-Pglu-OH. Each coupling step utilizes potent condensing agents such as HBTU, HATU, or BOP in the presence of organic bases like DIEA or NMM. The choice of CTC resin is mechanistically significant because it forms a benzhydryl ester linkage with the C-terminal amino acid, which is stable to the basic conditions of Fmoc deprotection but labile to mild acidic conditions (e.g., 1% TFA in DCM). This orthogonality allows for the cleavage of the protected peptide fragment (Compound 1) from the resin without disturbing the acid-labile side-chain protecting groups like tBu and Boc, ensuring the integrity of the intermediate for subsequent liquid-phase coupling.

Impurity control is rigorously managed through the fragmentation strategy and specific reagent choices. The liquid-phase synthesis of the C-terminal fragment, H-Arg(pbf)-Pro-NHEt (Compound 2), allows for independent purification of this dipeptide before it is coupled to the larger N-terminal fragment. This modular approach prevents the propagation of deletion sequences or incomplete couplings that often plague full-length solid-phase synthesis of long peptides. During the final fragment condensation to form Compound 3, the molar ratio of the N-terminal fragment to the C-terminal fragment is carefully controlled (1:1.01 to 1:1.5) to drive the reaction to completion while minimizing excess reagent waste. The final global deprotection utilizes a trifluoroacetic acid (TFA) cocktail containing scavengers like triisopropylsilane (TIS) and water to remove all protecting groups simultaneously. The resulting crude peptide is precipitated using diethyl ether, a technique that effectively removes organic soluble impurities and reagents, yielding a crude product with purity exceeding 80%, which serves as an excellent starting material for final purification.

How to Synthesize Leuprorelin Efficiently

The synthesis of Leuprorelin via this fragment condensation method requires strict adherence to stoichiometric ratios and reaction conditions to ensure high yields and purity. The process is divided into four distinct stages: the solid-phase assembly of the N-terminal fragment, the liquid-phase preparation of the C-terminal fragment, the solution-phase coupling of these two fragments, and the final global deprotection. Operators must pay close attention to the recycling protocol for the CTC resin, as this is a key differentiator in the cost structure of the process. The following guide outlines the critical operational phases derived from the patent specifications, emphasizing the parameters necessary for successful scale-up.

1. Synthesize Compound 1 (Boc-Pglu-His(Boc)-Trp(Boc)-Ser(tBu)-Tyr(tBu)-D-Leu-Leu-OH) using CTC resin solid-phase synthesis from C to N terminus, utilizing piperazine for deprotection.
2. Synthesize Compound 2 (H-Arg(pbf)-Pro-NHEt) via liquid-phase peptide synthesis using Fmoc-Arg(pbf)-OH and H-Pro-NHEt·HCl.
3. Couple Compound 1 and Compound 2 in liquid phase using a condensing agent like HBTU or BOP to form the fully protected Compound 3.
4. Perform global deprotection of Compound 3 using a TFA cleavage cocktail to yield crude Leuprorelin, followed by precipitation and purification.

Commercial Advantages for Procurement and Supply Chain Teams

For procurement managers and supply chain directors, the adoption of this solid-liquid fragment synthesis method offers tangible strategic benefits beyond mere technical feasibility. The primary advantage lies in the substantial reduction of raw material costs driven by the replacement of expensive and regulated reagents with more economical alternatives. By eliminating the need for high volumes of piperidine and enabling the recycling of the solid support resin, the overall cost of goods sold (COGS) for the peptide intermediate is significantly optimized. This cost efficiency is compounded by the improved safety profile of the reagents; piperazine is easier to handle, store, and transport compared to piperidine, reducing the regulatory burden and insurance costs associated with hazardous chemical inventory. These factors collectively contribute to a more resilient and cost-competitive supply chain for Leuprorelin intermediates.

• Cost Reduction in Manufacturing: The economic model of this synthesis is fundamentally improved by the ability to recycle the CTC resin. In traditional solid-phase synthesis, the resin is often discarded after a single use, representing a significant waste of material. In this novel process, the resin is treated with thionyl chloride in dichloromethane to regenerate the active chloride functionality, allowing it to be reused for subsequent batches. Additionally, the switch to piperazine as the uncapping reagent leverages a lower-cost commodity chemical, directly reducing the variable cost per kilogram of product without compromising reaction kinetics or purity profiles.
• Enhanced Supply Chain Reliability: Supply chain continuity is bolstered by the use of widely available and stable reagents. The reliance on standard amino acid derivatives protected with Boc, tBu, and Pbf groups ensures that sourcing remains flexible and不受 limited by proprietary or scarce materials. The liquid-phase synthesis of the C-terminal fragment allows for bulk production of this key intermediate independently of the solid-phase campaign, creating a buffer stock that can mitigate production delays. This modularity ensures that if one part of the synthesis line encounters issues, the other can continue to operate, maintaining overall throughput and delivery reliability for downstream API manufacturers.
• Scalability and Environmental Compliance: The process is explicitly designed for large-scale industrial production, avoiding violent exothermic reactions that pose safety risks at scale. The absence of heavy metal catalysts or exotic reagents simplifies waste treatment protocols, aligning with increasingly stringent environmental regulations. The ability to recycle the resin significantly reduces the volume of solid chemical waste generated, lowering disposal costs and the environmental footprint of the manufacturing facility. This sustainability angle is increasingly important for multinational pharmaceutical companies seeking suppliers who can meet rigorous ESG (Environmental, Social, and Governance) criteria while delivering high-quality intermediates.

Frequently Asked Questions (FAQ)

The following questions address common technical and commercial inquiries regarding the implementation of this Leuprorelin synthesis method. These answers are derived directly from the experimental data and beneficial effects described in the patent literature, providing clarity on the operational realities of this technology. Understanding these details is crucial for technical teams evaluating the feasibility of adopting this route for commercial production.

Q: What are the advantages of using CTC resin over traditional HMPB-AM resin for Leuprorelin synthesis?

A: CTC resin offers superior stability and ease of transport compared to traditional resins. Crucially, the patent highlights that CTC resin can be recycled after use through a thionyl chloride treatment process, significantly reducing raw material consumption and waste generation in large-scale production.

Q: How does the use of piperazine impact the cost and safety profile of the synthesis?

A: Replacing the classical piperidine uncapping reagent with a piperazine solution (2-5% in DMF) lowers reagent costs as piperazine is less expensive. Furthermore, piperazine is not classified as an easy-to-prepare toxic reagent in the same regulatory context as piperidine, simplifying storage, transportation, and handling compliance for industrial facilities.

Q: What purity levels can be expected from the crude Leuprorelin produced by this method?

A: According to the patent data, the crude Leuprorelin obtained after TFA cleavage and ether precipitation can achieve a purity of greater than 80%, with specific examples demonstrating purity levels around 84.9%. This high initial purity simplifies downstream purification processes like preparative HPLC.

Partnering with NINGBO INNO PHARMCHEM: Your Reliable Leuprorelin Supplier

The synthesis method described in patent CN112279893A represents a mature and optimized pathway for producing high-quality Leuprorelin intermediates. At NINGBO INNO PHARMCHEM, we possess the technical expertise and infrastructure to translate such innovative laboratory protocols into robust commercial processes. Our team has extensive experience scaling diverse pathways from 100 kgs to 100 MT/annual commercial production, ensuring that the transition from pilot scale to full manufacturing is seamless. We maintain stringent purity specifications and operate rigorous QC labs equipped with advanced analytical instrumentation to verify the identity and quality of every batch, guaranteeing that our Leuprorelin intermediates meet the exacting standards required for final API formulation.

We invite pharmaceutical partners to leverage our capabilities for their Leuprorelin supply needs. By collaborating with us, you gain access to a Customized Cost-Saving Analysis tailored to your specific volume requirements and quality targets. We encourage you to contact our technical procurement team to request specific COA data for our current inventory and to discuss route feasibility assessments for your projects. Let us help you secure a stable, cost-effective, and high-quality supply of Leuprorelin intermediates for your global markets.